Janssen files Xarelto at FDA for Venous Thromboembolism and ACS

Janssen Research & Development, a Johnson & Johnson subsidiary, has filed at the FDA for approval of Xarelto (rivaroxaban) as a treatment for Deep Vein Thrombosis and Pulmonary Embolism, and as a preventative treatment for recurring Venous Thromboembolism. Deep Vein Thrombosis is a blood clot in large veins, usually in the legs. Those blood clots sometimes dislodge and travel to the lungs, where they can block the pulmonary artery in a condition called Pulmonary Embolism that can be fatal. Venous thromboembolism is a collective term for both problems. Johnson & Johnson has also asked the FDA to approve Xarelto as a treatment for life-threatening blood clots in patients with Acute Coronary Syndrome